- About Us
- Our BioBank Platform Technology
- Our Drug Programmes
- Contact us
Shareholders with interests of over 3% (Significant Shareholders), as advised to the Company, are listed to the right.
In so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 2.2%, which comprises the directors’ beneficial holdings of 2.2%.
|Name of shareholder||Number of ordinary shares||% of share capital|
Polar Capital LLP
Polygon Global Partners LLP